Advanced Filters
noise

New Haven, Connecticut Clinical Trials

A listing of New Haven, Connecticut clinical trials actively recruiting patient volunteers.

Found 524 clinical trials

Transcranial Magnetic Stimulation (TMS) to Treat Depression in Autism Spectrum Disorder

This study will assess clinical and behavioral measures along with electroencephalogram (EEG), event-related potentials (ERPS), and eye-tracking (ET) prior to and following a single intermittent Theta Burst Stimulation (iTBS) session to provide preliminary insight into the potential of TMS as an intervention for depression in individuals with Autism Spectrum Disorder …

18 - 40 years of age All Phase N/A
G Gaelle Massoud,

Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp

A Phase 3 clinical trial of oral GnRH antagonist pre-treatment for women with endometriosis who are undergoing IVF, with a primary outcome of live birth rate. The investigators' central hypothesis is that in infertile woman with endometriosis undergoing in vitro fertilization-embryo transfer (IVF-ET), live birth rates will improve in those …

18 - 40 years of age Female Phase 3
C Carolina Price, MPA

Integrated e-Health (Electronic Health) for HIV and Substance Use Disorders in Justice Involved Women

The purpose of this 2-site (CT, AL) study is to test innovative interventions to reduce stigma and improve the pre-exposure prophylaxis (PrEP) and opioid use disorder (OUD) care continua in women involved in the criminal justice system (WICJ). This study evaluates a newly validated PrEP decision aid and eHealth for …

18 - 59 years of age Female Phase 3

Effects of Acute and Chronic Empagliflozin Heart Failure

This is a 60-patient randomized, double-blind, placebo-controlled mechanistic study to understand the utility of empagliflozin in worsening heart failure (HF) patients with or without diabetes. Participants will be randomized to empagliflozin or placebo for 6 weeks, followed by a crossover of placebo patients to active therapy at 6 weeks-12 weeks.

18 years of age All Phase 1
O OCD Research

Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD

The proposed randomized, double-blind research study will use functional magnetic resonance neuroimaging using state-of-the-art HCP acquisition protocols and analytic pipelines, to identify predictors and correlates of response to an accepted first-line pharmacological treatment for obsessive-compulsive disorder.

18 - 65 years of age All Phase 1/2
C Christina Luddy, BS

Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans

The purpose of the study is to characterize the acute effects of cannabinoids in women relative to men and to begin probing the mechanisms that may underlie gender differences.

18 - 55 years of age All Phase 1
B Brooklyn A Bradley, BS

In Vivo Study of THC-induced Immune-genome Changes at Single Cell Solution in HIV-infected Humans

In this study, the investigators hypothesize that THC alters the immunogenome in a cell type-specific fashion and alters cytokine production via epigenetic regulatory mechanisms and that these alterations differ between HIV-infected and HIV-uninfected host genomes.

18 - 65 years of age All Phase 1
A Alice Hahn

Ultrasound Effects on Glycemic Control in T2DM

This is an open label, exploratory pilot study that will assess the effects of dual site focused pulsed ultrasound treatment on glycemic parameters in subjects with T2DM.

21 - 75 years of age All Phase N/A
A Alessandro D. Santin, M.D.

A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent cervical cancer.

18 years of age Female Phase 2

Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium

This study will assess the use of autologous bone marrow stem cells mobilization using 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane (PLERIXAFOR) as an effective medical therapy for the treatment of Asherman's Syndrome (AS), Atrophic Endometrium (AE) and Recurrent Implantation Failure (RIF).

18 - 40 years of age Female Phase N/A

Simplify language using AI